Drug Trial Radar · NCT03834753
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
228
Actual
Start
Jun 25, 2019
Primary completion
Jun 7, 2021
Study completion Jul 8, 2021
Sponsor
- Lead sponsor
- Outlook Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 8, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.
Conditions
- Age-related Macular Degeneration
- Neovascular Age-related Macular Degeneration
- Wet Macular Degeneration
Interventions
bevacizumabBiological
1.25 mg, intravitreal injection
ranibizumabBiological
0.5mg, intravitreal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Subjects Who Gain 15 or More Letters in Best Corrected Visual Acuity (BCVA)Time frame: 11 months
Locations
50 sites in 1 country. Site status is shown where the registry gives one.
Clinical Site
Tucson, Arizona
Clinical Site
Arcadia, California
Clinical Site
Beverly Hills, California
Clinical Site
Campbell, California
Clinical Site
Glendale, California
Clinical Site
Laguna Hills, California
Clinical Site
Long Beach, California
Clinical Site
Mountain View, California
Clinical Site
Oxnard, California
Clinical Site
Palm Desert, California
Clinical Site
Poway, California
Clinical Site
Sacramento, California
Clinical Site
Santa Maria, California
Clinical Site
Tustin, California
Clinical Site
Golden, Colorado
Clinical Site
Hamden, Connecticut
Clinical Site
Clearwater, Florida
Clinical Site
Pinellas Park, Florida
Clinical Site
Sarasota, Florida
Clinical Site
Winter Haven, Florida
Clinical Site
Augusta, Georgia
Clinical Site
Marietta, Georgia
Clinical Site
Downers Grove, Illinois
Clinical Site
Lemont, Illinois
Clinical Site
Springfield, Illinois
Clinical Site
Indianapolis, Indiana
Clinical Site
Hagerstown, Maryland
Clinical Site
Edina, Minnesota
Clinical Site
St Louis, Missouri
Clinical Site
Bloomfield, New Jersey
Clinical Site
Albuquerque, New Mexico
Clinical Site
New York, New York
Clinical Site
Chambersburg, Pennsylvania
Clinical Site
Monroeville, Pennsylvania
Clinical Site
Rapid City, South Dakota
Clinical Site
Germantown, Tennessee
Clinical Site
Abilene, Texas
Clinical Site
Amarillo, Texas
Clinical Site
Arlington, Texas
Clinical Site
Dallas, Texas
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.